# Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

> **NCT03617913** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 2 (actual)

## Conditions studied

- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall
- Stage II Bladder Cancer AJCC v8
- Stage II Renal Pelvis Cancer AJCC v8
- Stage II Ureter Cancer AJCC v8
- Stage II Urethral Cancer AJCC v8
- Stage III Bladder Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
- Stage IIIB Bladder Cancer AJCC v8
- Urethral Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Cisplatin
- **DRUG:** Fluorouracil
- **DRUG:** Mitomycin
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03617913
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-19
- **Primary completion:** 2019-11-14
- **Final completion:** 2020-07-27
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03617913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03617913, "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT03617913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*